Oncoinvent (ONCIN) investor relations material

Strategic clinical and financial milestones

• Accelerated patient recruitment in the phase 2 ovarian cancer study, with 69 of 108 patients enrolled by September 2026, enabling a more robust interim readout in March/April 2027 with nearly double the evaluable patients compared to the original plan.

• A private placement is planned to raise up to NOK 140 million, extending the cash runway into H2 2027 and supporting completion of phase 2, regulatory alignment, and phase 3 readiness.

• The clinical strategy includes parallel phase 3 preparation, aiming for seamless transition post-phase 2, with regulatory meetings and manufacturing scale-up already scheduled.

• Key catalysts include FDA feedback in late 2026, full phase 2 recruitment in Q2 2027, and phase 3 initiation in H2 2027.

Product and clinical rationale

• RadspherinⓇ is a peritoneal-targeted alpha therapy designed to prevent local recurrence in cancers with peritoneal metastases, addressing a high unmet need where no approved therapies exist.

• The product delivers a high local dose of alpha radiation with minimal systemic exposure, showing strong efficacy signals in phase 1 ovarian (90% recurrence-free at 24 months) and colorectal (72% at 18 months) studies.

• Safety profile is favorable, with no dose-limiting toxicity and only three serious adverse events possibly related to the drug across 68 patients.

• The mechanism is receptor-independent, enabling use across multiple tumor types with peritoneal spread.

Market potential and competitive positioning

• RadspherinⓇ targets a large, high-risk patient population, with blockbuster potential in ovarian cancer alone (estimated $1.3B peak sales in US + EU5) and significant additional potential in colorectal and other cancers.

• Entry into China could add $540–600M in peak annual sales across three indications.

• The product occupies a unique niche with a single-dose, workflow-light administration, differentiating it from HIPEC and systemic therapies.

• The radiopharma sector is concentrated in other indications, with limited competition in peritoneal metastases.